ENGN: Pivotal gene therapy for NMIBC nears FDA filing, targeting broad community adoption and best-in-class use
Category: Health
Share
Archive
Like
Detalimogene voraplasmid is advancing toward FDA submission, with pivotal data maturing by year-end and strong interim efficacy and tolerability. Positioned for broad adoption in community urology practices, the product's ease of use and robust safety profile differentiate it, while a surfactant cohort aims to further enhance outcomes.
Based on enGene Therapeutics Inc. [ENGN] Wells Fargo 21st Annual Healthcare Conference Audio Transcript — Sep. 8 2026
A note on cookies
Newshunt uses essential cookies to keep you signed in and to remember your language and country, so the site works the way you expect. With your permission, we'd also like to use analytics cookies to understand how people use Newshunt and improve it over time.
Accepting only affects analytics. To learn more, view our Privacy Policy or Terms & Conditions.
(0)Comments